HCPLive Network

Primary Care Physicians Are on the Front Lines in the Battle against Chronic Kidney Disease

 
Robert Stanton, MD, associate professor of Medicine, Harvard Medical School, Chief of Nephrology, Joslin Diabetes Center, began his “Chronic Kidney Disease” session at the 2013 Pri-Med East Conference and Exhibition, by presenting some astounding data. He first showed a map of the number of patients on dialysis in 1992 (it was sparse); he then showed a map of dialysis in 2002 (it was dense, and all over the world), eliciting an audible gasp from the audience at the increase. “The numbers keep rising,” he said.
 
Stanton said he likes to use dialysis incidence rather than test results, as dialysis is countable and cannot be argued with. He said that Kidney disease “is not an equal opportunity player:” American Indians, Hispanics, and African-Americans are all at higher risk.
 
“What are the consequences? They get dialysis; they get a transplant; or they die. Those are the options,” said Stanton. He said that as a specialist, he can’t have as great an impact as a primary care physician can when it comes to alleviating this situation because he doesn’t diagnose patients; it’s up to PCPs to “recognize and diagnose early and often.”
 
Stanton presented some sobering statistics, noting that about 14% of the US population has CKD. Most CKD patients die of heart disease before reaching end-stage renal disease (ESRD), as there is a very close association of CKD and cardiovascular disease (CVD)—when GFR (glomerular filtration rate) declines and/or urine albumin levels rise, cardiovascular events and mortality rise. About 593,000 patients are on dialysis (414,000) or have a kidney transplant (179,000). There are 87,000 patients on the transplant wait list. Death rates are 20%/year for dialysis patients. The number of ESRD patients rises about 1-3% each year. Stanton noted that Medicare spends about $30 billion annually on CKD (.2% of the population spends 6.1% of the Medicare budget!).
 
Drivers of kidney disease are: diabetes mellitus, hypertension, and glomerulonephritis. Recognition and diagnosis should be done by GFR, albuminuria/proteinuria, and urinalysis tests; these must be tested for to have an impact on CKD. Stanton emphasized that using creatinine alone to diagnose kidney disease means the clinician doing so will probably miss it. And, as GFR changes with age, physicians must use a formula that factors in age, sex, and race—MDRD (Modification of Diet in Renal Disease) or CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
 
“The urine dip stick is not an effective diagnostic tool!” Stanton proclaimed. He said urinalysis is also important for diagnosis, and advised using a spot urine specimen to measure the albumin/creatinine ratio. “Only diagnosis and intervention by all of us here can make a difference,” he said.
 
Treatment of CKD involves: education, diet, exercise, and weight loss. Treatment goals should be: blood pressure (BP)  <130/80, lowered urine albumin, smoking cessation, and, if the patient is diabetic, tight glucose control (A1c<7.0%). Interestingly, Stanton said that blood pressure measurements taken in the physician’s office are often recorded and used as a baseline despite ”White Coat Hypertension” and bad routine office practices. However, studies show that home blood pressure measurements are more accurate. Stanton also recommended using the home blood pressure to diagnose and monitor blood pressure. Blood pressure recommendations for patients with CKD are somewhat complex: <130/80, <125/75 if >1g of urine protein, and avoid <115 systolic if diagnosed with CVD.
 
In addition to blood pressure control, there is also a role for RAAS (renin angiotensin aldosterone system) inhibitors, blood sugar control if diabetic, ACE (angiotensin converting enzyme) inhibitors, and ARBs (angiotensin receptor blocker). Stanton presented several studies with recommendations; and admitted that they contradicted each other (eg, Losartan, ONTARGET, CHARM). The choices and combinations of drugs and conditions must be carefully assessed by the treating physician.
 
Stanton also discussed the role of a low-protein diet (<0.8 g/kg/day), which has been shown to be effective in animal studies. Although high protein intake is associated with worsening renal disease, low-protein diets have not been routinely shown to be effective in humans (because it is very hard to stay on a low protein diet?). He concluded by saying, ”I don’t think it is very useful; it’s not effective in humans, just animals.”
 
At the end of the session, Stanton told the audience, “You’re the ones that can make a difference,” emphasizing that early diagnosis and aggressive treatment are essential to slow the epidemic of kidney and cardiovascular disease.
 

Further Reading
As more studies have demonstrated potential therapeutic applications for marijuana, public opinion regarding medical and recreational marijuana use has shifted. One such study recently published in the American Journal of Gastroenterology revealed medical marijuana is potentially beneficial for digestive disorders and gastrointestinal symptoms.
Is one beta blocker better than another for patients born with long QT syndrome? In a report published Sept 23 in The Journal of the American College of Cardiology Abeer Abu-Zeitone, PhD, and colleagues found that in their study group, nadolol worked best at preventing a recurrent serious cardiac event and that propranolol, the oldest beta-blocker available, did the worst. The researchers also evaluated how patients had fared with atenolol and metoprolol. But in an editorial commenting on the findings, Arthur Wilde, MD, PhD, and Michael Ackerman MD, PhD, questioned the study’s methodology and predicted that many heart centers will continue to use propranolol.
The American College of Cardiologists (ACC) has had a change of heart. The group is now recommending doctors treating heart attack patients for arterial blockages should treat lesions in both cardiac arteries, not just the “culprit” artery that led to the MI. In a statement Sept. 22, the ACA cited new information—reported Sept. 5 by HCPLive.com—from a UK study showing that it pays to do the more extensive procedure.
Enterovirus-D68 could soon be in the rearview mirror, according to a Hartford, CT, pediatric intensivist who has treated more than 20 children hospitalized with the infection. “We may have plateaued,” said Christopher Carroll, MD, an asthma specialist at Connecticut Children’s Medical Center. While children are still being admitted for respiratory problems, “Now it’s more a mix of symptoms, not those of classic enterovirus.” Though he could not say for certain the outbreak has peaked, he did say that “things are not continuing to get worse.”
The World Health Organization continued its efforts to battle the ongoing Ebola outbreak with a second meeting of its Emergency Committee tackling the virus.
Counseling at-risk teens and adults to change risky behavior is an effective way to reduce the spread of sexually transmitted diseases, according to the US Preventive Services Task Force (USPSTF). The group is updating its guidelines for primary care physicians to recommend they offer appropriate patients such behavioral advice. The task force also calls for routine screening for chlamydia and gonorrhea for sexually active teens and women up to age 24. Older women who are pregnant or may be at risk of infection due to a variety of sexual behaviors—such as having multiple partners or exchanging sex for money or drugs—should also be screened, the USPSTF said.
Advances in knowledge surrounding gastrointestinal conditions have paved the way for improvements in Crohn’s disease (CD) treatment. To aid clinicians in managing patients with CD, the American Gastroenterological Association (AGA) created a clinical decision tool to effectively guide gastroenterologists throughout their decision-making process.
More Reading
As more studies have demonstrated potential therapeutic applications for marijuana, public opinion regarding medical and recreational marijuana use has shifted. One such study recently published in the American Journal of Gastroenterology revealed medical marijuana is potentially beneficial for digestive disorders and gastrointestinal symptoms.